Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies
Science Magazine
doi.org/10.1126/scienc…
👉liver resident macrophages limit half-life of cfDNA
👉nanoparticles🚫clearance
😅Really cool & could help to boost sensitivity of ctDNA…

T-DXd is approved for the treatment of patients with ANY treatment-refractory HER2+ (IHC 3+) tumor, making of it the first agnostic ADC. Unlikely to be the last. Key priority: ensuring that HER2 testing is expanded across cancer types. Exciting times! fda.gov/drugs/resource…

So proud of Scott Kopetz for the AACR award. I know Dr Hong is so proud of the work you lead and what you have done to help advance care for #crcsm pts! I’m so lucky to have had your mentorship for 13+ years and am grateful for the team science leader you are to #endcancer !

Woohoo! #NEO -RT Trial activated ahead of schedule and ready to open! Thanks to all of the support!
Dr. Carl J Brown 🌎 CCTG NCI CTEP Clinical Research Josh Smith, MD, PhD, FACS Mark Whiteford Sharlene Gill, MD, MPH, MBA, FASCO Dr. Cathy Eng Karyn Goodman, MD, MS Jonathan Loree

A quick Xtorial:
1/10

#GI24 ASCO
NETTER-2
Lutathera in adv SSTR+ hi G2 & G3 GEP-NETs (Ki67 10-55%) by Dr Simron Singh
📌 PFS HR 0.27 (p<0.0001)
📌 ORR 43%*
➡️ this is practice changing
OncoAlert OncoDaily

DYNAMIC-RECTAL showed of 28% patients ctDNA + after TME and pre-op CRT for stage 2/3 #rectalcancer . Lung 🫁- only recurrence accounted to 78% of the false-negatives on post-op testing. ⁦Jeanne Tie⁩ ⁦Jonathan Loree⁩ ⁦Pashtoon Kasi MD, MS⁩ ⁦COLONTOWN⁩ #GI24

#GI24 #CRCsm
Come check out our poster on real-world adoption of 3mos adjuvant CAPOX
👇 ASCO #DailyNews 🙏
for the shout-out
👏 Congrats Tharani Krishnan
BC Cancer OncoAlert
➡️ascopubs.org/doi/10.1200/AD…

Emesis and Nausea are significant problem that affects the quality of life during the treatment of patients with cancer!
⏺️ Tata Memorial Hospital 🇮🇳
New study in The Lancet Oncology Low-dose olanzapine (2.5 mg) effectively prevents chemotherapy-induced nausea, with less daytime sleepiness…

As suspected, PRRT infrequently (rarely?) leads to objective response in mesenteric masses (MM) in patients with sbNETs but that said, there can be substantial benefit outside of the MM and in terms of symptom control. Great study Louis de Mestier et al!
jnm.snmjournals.org/content/early/…

Hope this article is helpful for those starting a PRRT program. I’ve helped start 2 in the 🇺🇸 and enjoyed contributing to the publication. ⁦Erik Mittra, MD, PhD⁩ ⁦Adam Brown, MBA, NMTCB(CNMT)(CT)(PET),RT(N)⁩ ⁦Novartis Cancer⁩ ⁦Rebecca Wong⁩ ⁦LACNETS⁩ onlinelibrary.wiley.com/doi/10.1002/ca…

Lymph-node-targeted, mKRAS-specific vaccine in #PDAC & #CRC cancer
Nature Medicine
doi.org/10.1038/s41591…
🔎 Phs 1 AMPLIFY-201, G12D & G12R KRAS mutations
👉84% tumor marker response, 24% biomarker
clearance, mRFS was 16.33mo
😅Strong T-cell responses, amazing...the future?…

23. Just for fun
x.com/AdamMGrant/sta…

Being a lifelong learner isn’t about taking pride in your knowledge. It's about having the humility to know what you don’t know.

My top 23 insights from 2023 🧵

Therapy-related heme malignancies (including t-MN) and clonal cytopenia after PRRT. Among 346 pts who had at least 1 PRRT, 4% had a therapy-related neoplasm or clonal cytopenia - 2.3 % with t-MN. Mrinal Patnaik Bassam Sonbol Tuba Kendi Abhishek Mangaonkar

sciencedirect.com/science/articl…

The Tumor Board ( #LCSM theme)

Nice - always need to wait for your suggestions to plan my meeting :)

Up to 50% (or more) of intended IM drug injections end up in the subcutaneous (SC) space and this is very common in NET pts. Octreotide LAR is an IM inj but the effect on inadvertent SC injections on PFS and OS is not known. Maybe there is little effect...
onlinelibrary.wiley.com/doi/10.1111/jn…

For #AnalCancer , T category has a greater effect on survival than N category. Accordingly, version 9 AJCC stage groups have been appropriately adjusted to reflect contemporary long-term outcomes.

Find the latest updates to anal cancer at: acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca…

Liver Metastases & Immune Checkpoint Inhibitor Efficacy in Refractory mCRC
JAMA Network Open
doi.org/10.1001/jamane…
🔎CCTG CO.26 trial
👉Pts without LM have significantly improved
DCR, PFS & OS with Durva/Treme vs BSC
🧐consistent finding, important for future trial design…

The first piece of knowledge from PARERE trial by GONO Foundation
✅ > 200 pts candidate to antiEGFR rechallenge screened with #liquidbiopsy 🩸
⛔️38% RAS or BRAF mutations in ctDNA
🔢 30% RAS/BRAF wt cases with at least one potential mechanism of resistance
Paolo Ciracì